Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | The impact of renal impairment on the MM treatment strategy

Katja Weisel • 12 Sep 2019
IMW 2019
Multiple Myeloma

Katja Weisel, MD, of University Medical Center Hamburg-Eppendorf, Hamburg, Germany, explains how renal impairment impacts the multiple myeloma (MM) treatment strategy at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Katja Weisel

1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals